德康医疗(DXCM)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 DXCM 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Revenue	revenue	1.19B	15.05%
Gross profit	profit	750.30M	27.39%
Cost of sales	cost	441.60M	-1.21%
Other income, net	revenue	14.20M	-31.07%
Operating income	profit	255.30M	90.95%
Total operating expenses	cost	495.00M	8.72%
Income before income taxes	profit	269.50M	74.66%
Selling, general and administrative	cost	349.70M	12.77%
Research and development	cost	145.30M	0.07%
Net income	profit	199.50M	89.28%
Income tax expense	cost	70.00M	43.15%

Business Breakdown
Segment	Value	YoY
Sales Channel, Through Intermediary	1.01B	14.81%
Sales Channel, Directly to Consumer	181.60M	16.41%

Geography Breakdown
Segment	Value	YoY
UNITED STATES	832.30M	10.90%
Non-US	359.60M	25.95%

Balance Sheet Q1 2026
Item	Category	Value
Short-term marketable securities	assets	1.30B
Cash and cash equivalents	assets	1.12B
Accounts receivable, net	assets	1.09B
Inventory	assets	693.60M
Prepaid and other current assets	assets	134.30M
Total current assets	assets	4.33B
Property and equipment, net	assets	1.56B
Deferred tax assets	assets	296.10M
Other assets	assets	285.90M
Operating lease right-of-use assets	assets	73.10M
Intangibles, net	assets	62.60M
Goodwill	assets	24.20M
Total assets	assets	6.63B
Total liabilities	liabilities	3.68B
Total stockholders’ equity	equity	2.96B
Treasury stock, common, value	equity	2.12B
Total current liabilities	liabilities	2.22B
Long-term senior convertible notes	liabilities	1.24B
Other long-term liabilities	liabilities	141.80M
Long-term operating lease liabilities	liabilities	69.00M
Aggregate	equity	5.08B
Accounts payable and accrued liabilities	liabilities	2.07B
Accrued payroll and related expenses	liabilities	121.80M
Short-term operating lease liabilities	liabilities	20.50M
Other current liabilities	liabilities	7.60M
Retained earnings	equity	2.63B
Additional paid-in capital	equity	2.34B
Accumulated other comprehensive income	equity	106.20M
Common stock, $0.001 par value, 800.0 million shares authorized; 412.3 million and 385.9 million shares issued and outstanding, respectively, at march 31, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at december 31, 2025	equity	400000

Operating Activities – 3M 2026
Item	Value
Net income	199.50M
Accounts payable and accrued liabilities	145.10M
Increase (decrease) in accounts receivable	124.60M
Depreciation and amortization	67.10M
Increase (decrease) in prepaid expense and other assets	51.00M
Share-based compensation	43.30M
Deferred revenue and other liabilities	7.30M
Non-cash interest expense	1.00M
Deferred income taxes	300000
Increase (decrease) in operating lease assets and liabilities, net	-1.30M
Accrued payroll and related expenses	-47.10M
Increase (decrease) in inventories	-65.20M

Investing Activities – 3M 2026
Item	Value
Proceeds from sale and maturity of marketable securities	468.20M
Payments to acquire other investments	-1.50M
Payments to acquire property, plant, and equipment	-76.60M
Payments to acquire debt securities, available-for-sale	-688.60M

Financing Activities – 3M 2026
Item	Value
Net proceeds from issuance of common stock	12.70M
Other financing activities	-1.90M
Payment, tax withholding, share-based payment arrangement	-35.80M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	919.10M
Cash and cash equivalents, end of period	1.12B